Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

NCT02899793 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Endometrial Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Yale University

Collaborators

[object Object]